AVAX Technologies Inc.

AVAX Technologies is a development stage biopharmaceutical company which is acquiring and developing technologies and products for the treatment of cancer and other life-threatening diseases. The Company is focusing its efforts primarily on the development of immunotherapies and chemotherapies for cancer. Immunotherapy is a rapidly developing segment of the cancer therapeutic market.

Contact Details: 4520 Main Street Suite 930 Kansas City 64111 United States of America Tel: 816 960 1333 Fax: 215-241-9684 Email: WWW: www.avax.com/

BioNews Results for AVAX Technologies Inc.:
Madeira Therapeutics Names David Tousley to Board of Advisors	Pharma Live:  Aug 26 2008 8:30PM Matching: avax technologies inc
Shire Appoints Dr. Jeffrey Jonas Senior Vice President, R&D, Specialty Pharmaceuticals	Pharma Live:  Jul 23 2008 3:19PM Matching: avax technologies inc

AVAX Technologies Inc. (AVXT.OB) Financial information Links from Barchart
AVXT.OB Quote from from Barchart.com
AVXT.OB Chart from from Barchart.com
AVXT.OB Profile from from Barchart.com
AVXT.OB Opinion from from Barchart.com
→View more AVAX Technologies Inc. finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 350 times since April 2007, the link to the organisation's website has been followed 72 times

Recent Search Terms used to find this page: avax therapeutics | t | Avax.com | AVAX PHARMACEUTICALS | avax pharmaceuticals | avax pharmaceuticals | avax technologies kansas city | avax | avax building | avax technologies | .

Search for more companies in Kansas City

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for AVAX Technologies Inc.